Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

Anika M. Valk, Jim B.D. Keijser, Koos P.J. van Dam, Eileen W. Stalman, Luuk Wieske, Maurice Steenhuis, Laura Y.L. Kummer, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Barbara Horváth, DirkJan Hijnen, Corine R.G. Schreurs, Zoé L.E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Sofie Keijzer, Ninotska I.L. Derksen, Melanie van Deelen, Gerard van Mierlo, Taco W. Kuijpers, Filip Eftimov, S. Marieke van Ham, Anja ten Brinke, Theo Rispens, T2B! Immunity against SARS-CoV-2 study group
doi: https://doi.org/10.1101/2023.09.29.23296354

Article Information

doi 
https://doi.org/10.1101/2023.09.29.23296354
History 
  • October 2, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Anika M. Valk, MSc, LLB1,2,3,*,
  2. Jim B.D. Keijser, MSc1,3,*,
  3. Koos P.J. van Dam, MD4,
  4. Eileen W. Stalman, MD4,
  5. Luuk Wieske, MD, PhD4,5,
  6. Maurice Steenhuis, PhD1,
  7. Laura Y.L. Kummer, MD1,3,4,
  8. Phyllis I. Spuls, MD, PhD6,
  9. Marcel W. Bekkenk, MD, PhD6,
  10. Annelie H. Musters, MD6,
  11. Nicoline F. Post, MD6,
  12. Angela L. Bosma, MD6,
  13. Barbara Horváth, MD, PhD7,
  14. DirkJan Hijnen, MD, PhD8,
  15. Corine R.G. Schreurs, MD8,
  16. Zoé L.E. van Kempen, MD, PhD9,
  17. Joep Killestein, MD, PhD9,
  18. Adriaan G. Volkers, MD10,
  19. Sander W. Tas, MD, PhD11,
  20. Laura Boekel, BSc12,
  21. Gerrit J. Wolbink, MD, PhD1,12,
  22. Sofie Keijzer, MSc1,3,
  23. Ninotska I.L. Derksen, MSc1,3,
  24. Melanie van Deelen, BSc1,
  25. Gerard van Mierlo1,3,
  26. Taco W. Kuijpers, MD, PhD1,3,13,
  27. Filip Eftimov, MD, PhD4,
  28. S. Marieke van Ham, PhD1,2,3,
  29. Anja ten Brinke, PhD1,3,
  30. Theo Rispens, PhD1,3,+,
  31. T2B! Immunity against SARS-CoV-2 study group
  1. 1Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, Amsterdam, the Netherlands
  2. 2Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands
  3. 3Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
  4. 4Department of Neurology and Neurophysiology, Amsterdam Neuroscience, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  5. 5Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, The Netherlands
  6. 6Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam UMC, location AMC, University of Amsterdam, Amsterdam, the Netherlands
  7. 7Department of Dermatology, UMCG Expertise Center for Blistering Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
  8. 8Department of Dermatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands
  9. 9Department of Neurology, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands
  10. 10Department of Gastroenterology and Hepatology, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  11. 11Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  12. 12Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, the Netherlands
  13. 13Department of Pediatric Immunology, Rheumatology and Infectious Disease, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
  1. ↵+Corresponding author
    Theo Rispens, t.rispens{at}sanquin.nl, Dept. of Immunopathology U2, Sanquin Research, Plesmanlaan 125, 1066CX Amsterdam, The Netherlands

  1. ↵* Contributed equally as first authors

Back to top
Posted October 02, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination
Anika M. Valk, Jim B.D. Keijser, Koos P.J. van Dam, Eileen W. Stalman, Luuk Wieske, Maurice Steenhuis, Laura Y.L. Kummer, Phyllis I. Spuls, Marcel W. Bekkenk, Annelie H. Musters, Nicoline F. Post, Angela L. Bosma, Barbara Horváth, DirkJan Hijnen, Corine R.G. Schreurs, Zoé L.E. van Kempen, Joep Killestein, Adriaan G. Volkers, Sander W. Tas, Laura Boekel, Gerrit J. Wolbink, Sofie Keijzer, Ninotska I.L. Derksen, Melanie van Deelen, Gerard van Mierlo, Taco W. Kuijpers, Filip Eftimov, S. Marieke van Ham, Anja ten Brinke, Theo Rispens, T2B! Immunity against SARS-CoV-2 study group
medRxiv 2023.09.29.23296354; doi: https://doi.org/10.1101/2023.09.29.23296354
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area